Allergan Must Face Antitrust Class Action Over Alzheimer’s Drug

U.S. Patent and Trademark Office Director Michelle Lee faceda barrage of questions and criticism from primarily Republican lawmakers on Tuesday at a U.S. House of Representatives’ Judiciary Committee hearing, over reports issued in recent months that took the agency to task over patent quality and employee attendance issues.

A federal appeals court has ordered a federal judge in Philadelphia to reconsider his order certifying a class of 22 drug wholesalers accusing generic drugmakers Mylan Inc and Ranbaxy Laboratories Ltd of accepting payments from Cephalon Incto delay generic versions of Cephalon’s wakefulness drug Provigil.

Source: www.reuters.com www.reuters.com

Be the first to comment on "Allergan Must Face Antitrust Class Action Over Alzheimer’s Drug"

Leave a comment

Your email address will not be published.


*